1	Targeting	Target	B-VP	VBG	O	0	ROOT	0
2	angiogenesis	angiogenesis	B-NP	NN	O	1	OBJ	3	angiogenesis
3	:	:	O	:	O	1	VMOD	0
4	progress	progress	B-NP	NN	O	3	OBJ	0
5	with	with	B-PP	IN	O	4	NMOD	0
6	anti-VEGF	anti-VEGF	B-NP	JJ	O	7	NMOD	0
7	treatment	treatment	I-NP	NN	O	5	PMOD	0
8	with	with	B-PP	IN	O	7	NMOD	0
9	large	large	B-NP	JJ	O	10	NMOD	0
10	molecules	molecule	I-NP	NNS	O	8	PMOD	0
11	.	.	O	.	O	1	P	0

1	Angiogenesis	Angiogenesis	B-NP	NN	O	3	NMOD	3	Angiogenesis
2	--	--	O	:	O	1	P	0
3	one	one	B-NP	CD	O	10	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	the	the	B-NP	DT	O	6	NMOD	0
6	hallmarks	hallmark	I-NP	NNS	O	4	PMOD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	cancer	cancer	B-NP	NN	O	7	PMOD	0
9	--	--	O	:	O	3	P	0
10	has	have	B-VP	VBZ	O	0	ROOT	0
11	emerged	emerge	I-VP	VBN	O	10	VC	0
12	as	as	B-PP	IN	O	11	VMOD	0
13	a	a	B-NP	DT	O	16	NMOD	0
14	valid	valid	I-NP	JJ	O	16	NMOD	0
15	therapeutic	therapeutic	I-NP	JJ	O	16	NMOD	0
16	target	target	I-NP	NN	O	12	PMOD	0
17	in	in	B-PP	IN	O	16	NMOD	0
18	oncology	oncology	B-NP	NN	O	17	PMOD	0
19	.	.	O	.	O	10	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	VEGF	VEGF	I-NP	NN	B-protein	3	NMOD	0
3	system	system	I-NP	NN	O	4	SUB	0
4	represents	represent	B-VP	VBZ	O	0	ROOT	0
5	a	a	B-NP	DT	O	7	NMOD	0
6	key	key	I-NP	JJ	O	7	NMOD	0
7	mediator	mediator	I-NP	NN	O	14	NMOD	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	tumor-initiated	tumor-initiated	B-NP	JJ	O	10	NMOD	17	initiated
10	angiogenesis	angiogenesis	I-NP	NN	O	8	PMOD	3	angiogenesis
11	and	and	O	CC	O	14	NMOD	0
12	the	the	B-NP	DT	O	14	NMOD	0
13	first	first	I-NP	JJ	O	14	NMOD	0
14	target	target	I-NP	NN	O	4	OBJ	0
15	of	of	B-PP	IN	O	14	NMOD	0
16	antiangiogenesis	antiangiogenesis	B-NP	JJ	O	17	NMOD	3	angiogenesis
17	agents	agent	I-NP	NNS	O	15	PMOD	0
18	introduced	introduce	B-VP	VBN	O	17	NMOD	0
19	in	in	B-PP	IN	O	18	VMOD	0
20	clinical	clinical	B-NP	JJ	O	21	NMOD	0
21	practice	practice	I-NP	NN	O	19	PMOD	0
22	.	.	O	.	O	4	P	0

1	Although	Although	B-SBAR	IN	O	0	ROOT	0
2	anti-VEGF	anti-VEGF	B-NP	JJ	O	3	NMOD	0
3	therapies	therapy	I-NP	NNS	O	4	SUB	19	therapies
4	have	have	B-VP	VBP	O	1	SBAR	0
5	clearly	clearly	I-VP	RB	O	4	VMOD	0
6	demonstrated	demonstrate	I-VP	VBN	O	4	VC	0
7	antitumor	antitumor	B-NP	JJ	O	8	NMOD	0
8	efficacy	efficacy	I-NP	NN	O	25	SUB	18	efficacy
9	in	in	B-PP	IN	O	8	NMOD	0
10	various	various	B-NP	JJ	O	11	NMOD	0
11	malignancies	malignancy	I-NP	NNS	O	9	PMOD	0
12	,	,	O	,	O	8	P	0
13	especially	especially	B-ADVP	RB	O	14	AMOD	0
14	when	when	B-ADVP	WRB	O	25	VMOD	0
15	combined	combine	B-VP	VBN	O	14	SBAR	0
16	with	with	B-PP	IN	O	15	VMOD	0
17	conventional	conventional	B-NP	JJ	O	19	NMOD	0
18	cytotoxic	cytotoxic	I-NP	JJ	O	19	NMOD	0
19	chemotherapy	chemotherapy	I-NP	NN	O	16	PMOD	0
20	,	,	O	,	O	25	P	0
21	their	their	B-NP	PRP$	O	22	NMOD	0
22	mechanism	mechanism	I-NP	NN	O	25	SUB	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	action	action	B-NP	NN	O	23	PMOD	0
25	is	be	B-VP	VBZ	O	6	VMOD	0
26	not	not	O	RB	O	25	VMOD	0
27	fully	fully	B-ADJP	RB	O	28	VMOD	0
28	understood	understand	I-ADJP	VBN	O	25	VC	0
29	.	.	O	.	O	1	P	0

1	This	This	B-NP	DT	O	2	NMOD	0
2	Review	Review	I-NP	NNP	O	3	SUB	0
3	will	will	B-VP	MD	O	0	ROOT	0
4	discuss	discuss	I-VP	VB	O	3	VC	0
5	the	the	B-NP	DT	O	6	NMOD	0
6	rationale	rationale	I-NP	NN	O	4	OBJ	0
7	for	for	B-PP	IN	O	4	VMOD	0
8	using	use	B-VP	VBG	O	7	PMOD	0
9	antiangiogenic	antiangiogenic	B-NP	JJ	O	10	NMOD	3	angiogenic
10	compounds	compound	I-NP	NNS	O	8	OBJ	0
11	and	and	O	CC	O	3	VMOD	0
12	will	will	B-VP	MD	O	3	VMOD	0
13	focus	focus	I-VP	VB	O	12	VC	0
14	on	on	B-PP	IN	O	13	VMOD	0
15	large	large	B-NP	JJ	O	16	NMOD	0
16	molecules	molecule	I-NP	NNS	O	14	PMOD	0
17	,	,	O	,	O	16	P	0
18	such	such	B-PP	JJ	O	19	PMOD	0
19	as	as	I-PP	IN	O	16	NMOD	0
20	antibodies	antibody	B-NP	NNS	B-protein	19	PMOD	0
21	,	,	O	,	O	20	P	0
22	that	that	B-NP	WDT	O	20	NMOD	0
23	target	target	B-VP	VBP	O	22	SBAR	0
24	the	the	B-NP	DT	O	26	NMOD	0
25	VEGF	VEGF	I-NP	NN	B-protein	26	NMOD	0
26	system	system	I-NP	NN	O	23	OBJ	0
27	.	.	O	.	O	3	P	0

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD	0
2	data	datum	I-NP	NNS	O	5	SUB	0
3	on	on	B-PP	IN	O	2	NMOD	0
4	bevacizumab	bevacizumab	B-NP	NN	O	3	PMOD	0
5	is	be	B-VP	VBZ	O	0	ROOT	0
6	discussed	discuss	I-VP	VBN	O	5	VC	0
7	in	in	B-PP	IN	O	6	VMOD	0
8	detail	detail	B-NP	NN	O	7	PMOD	0
9	.	.	O	.	O	5	P	0

1	Predictive	Predictive	B-NP	JJ	O	2	NMOD	0
2	markers	marker	I-NP	NNS	O	6	SUB	0
3	for	for	B-PP	IN	O	2	NMOD	0
4	anti-VEGF	anti-VEGF	B-NP	JJ	O	5	NMOD	0
5	agents	agent	I-NP	NNS	O	3	PMOD	0
6	have	have	B-VP	VBP	O	0	ROOT	0
7	not	not	I-VP	RB	O	6	VMOD	0
8	yet	yet	I-VP	RB	O	6	VMOD	0
9	been	be	I-VP	VBN	O	6	VC	0
10	identified	identify	I-VP	VBN	O	9	VC	0
11	and	and	O	CC	O	30	VMOD	0
12	questions	question	B-NP	NNS	O	30	SUB	0
13	regarding	regard	B-VP	VBG	O	12	NMOD	0
14	the	the	B-NP	DT	O	15	NMOD	0
15	usefulness	usefulness	I-NP	NN	O	27	NMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	bevacizumab	bevacizumab	B-NP	NN	B-protein	16	PMOD	0
18	in	in	B-PP	IN	O	15	NMOD	0
19	the	the	B-NP	DT	O	21	NMOD	0
20	adjuvant	adjuvant	I-NP	JJ	O	21	NMOD	0
21	setting	setting	I-NP	NN	O	18	PMOD	0
22	as	as	B-CONJP	RB	O	27	NMOD	0
23	well	well	I-CONJP	RB	O	22	DEP	0
24	as	as	I-CONJP	IN	O	22	DEP	0
25	its	its	B-NP	PRP$	O	27	NMOD	0
26	continued	continue	I-NP	VBN	O	27	NMOD	0
27	use	use	I-NP	NN	O	13	PMOD	0
28	beyond	beyond	B-PP	IN	O	27	NMOD	0
29	progression	progression	B-NP	NN	O	28	PMOD	0
30	remain	remain	B-VP	VBP	O	10	VMOD	0
31	unanswered	unanswered	B-ADJP	JJ	O	30	PRD	0
32	,	,	O	,	O	10	P	0
33	in	in	B-PP	IN	O	10	VMOD	0
34	spite	spite	B-NP	NN	O	33	PMOD	0
35	of	of	B-PP	IN	O	34	NMOD	0
36	negative	negative	B-NP	JJ	O	37	NMOD	0
37	data	datum	I-NP	NNS	O	35	PMOD	0
38	on	on	B-PP	IN	O	10	VMOD	0
39	bevacizumab	bevacizumab	B-NP	NN	O	38	PMOD	0
40	in	in	B-PP	IN	O	10	VMOD	0
41	treating	treat	B-VP	VBG	O	42	NMOD	19	treating
42	patients	patient	B-NP	NNS	O	40	PMOD	0
43	with	with	B-PP	IN	O	42	NMOD	0
44	adjuvant	adjuvant	B-NP	JJ	O	46	NMOD	0
45	colon	colon	I-NP	NN	O	46	NMOD	0
46	cancer	cancer	I-NP	NN	O	43	PMOD	0
47	.	.	O	.	O	6	P	0

1	Nonetheless	Nonetheless	B-ADVP	RB	O	5	VMOD	0
2	,	,	O	,	O	5	P	0
3	anti-VEGF	anti-VEGF	B-NP	JJ	O	4	NMOD	0
4	therapy	therapy	I-NP	NN	O	5	SUB	0
5	has	have	B-VP	VBZ	O	0	ROOT	0
6	enhanced	enhance	I-VP	VBN	O	5	VC	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	arsenal	arsenal	I-NP	NN	O	6	OBJ	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	anticancer	anticancer	B-NP	JJ	O	11	NMOD	0
11	therapies	therapy	I-NP	NNS	O	9	PMOD	0
12	and	and	O	CC	O	5	VMOD	0
13	has	have	B-VP	VBZ	O	5	VMOD	0
14	provided	provide	I-VP	VBN	O	13	VC	0
15	new	new	B-NP	JJ	O	16	NMOD	0
16	insights	insight	I-NP	NNS	O	14	OBJ	0
17	into	into	B-PP	IN	O	16	NMOD	0
18	the	the	B-NP	DT	O	19	NMOD	0
19	biology	biology	I-NP	NN	O	17	PMOD	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	malignancy	malignancy	B-NP	NN	O	20	PMOD	0
22	.	.	O	.	O	5	P	0

